ArticleLung Cancer (Auckland, N.Z.)2026

Prospective Observational Real-World Study of Afatinib as First-Line Treatment in Patients with Epidermal Growth Factor Receptor (EGFR) Mutation-Positive Advanced Non-Small Cell Lung Cancer (NSCLC) in China.

Jianying Zhou et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.